Autoimmune bullous diseases induced by cyclin-dependent kinase 4/6 inhibitors-first cohort from the EADV Task Force 'Dermatology for Cancer Patients'

Ann Oncol. 2024 Oct;35(10):915-917. doi: 10.1016/j.annonc.2024.07.243.
No abstract available

Publication types

  • Letter

MeSH terms

  • Advisory Committees
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Autoimmune Diseases* / drug therapy
  • Cohort Studies
  • Cyclin-Dependent Kinase 4* / antagonists & inhibitors
  • Cyclin-Dependent Kinase 6* / antagonists & inhibitors
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / drug therapy
  • Piperazines / adverse effects
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors* / adverse effects
  • Protein Kinase Inhibitors* / therapeutic use
  • Pyridines
  • Skin Diseases, Vesiculobullous / drug therapy
  • Skin Diseases, Vesiculobullous / pathology

Substances

  • Protein Kinase Inhibitors
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • CDK4 protein, human
  • CDK6 protein, human
  • palbociclib
  • Antineoplastic Agents
  • Piperazines
  • Pyridines